Skip to main content
logo
Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
78.66
-3.30 (-4.03%)
At close: Mar 3, 2026, 4:00 PM EST
79.80
+1.14 (1.45%)
After-hours: Mar 3, 2026, 4:35 PM EST

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
TRYNGOLZA Revenue
107.50M-
DAWNZERA Revenue
7.80M-
Total Product Revenue
115.30M-
SPINRAZA Royalties Revenue
212.30M216.10M
SPINRAZA Royalties Revenue Growth
-1.76%-10.11%
WAINUA Royalties Revenue
49.10M20.20M
WAINUA Royalties Revenue Growth
143.07%-
TEGSEDI and WAYLIVRA Revenue
35.00M34.20M
TEGSEDI and WAYLIVRA Revenue Growth
2.34%-2.01%
Commercial Licensing and Other Royalty Revenue
24.10M22.60M
Commercial Licensing and Other Royalty Revenue Growth
6.64%-32.13%
Total Commercial Revenue
435.80M293.10M
Total Commercial Revenue Growth
48.69%-5.02%
Amortization from Upfront Payments Revenue
-131.40M
Amortization from Upfront Payments Revenue Growth
-4.87%
Milestone Payments Revenue
-106.40M
Milestone Payments Revenue Growth
-5.87%
R&D License Fees Revenue
-71.30M
R&D License Fees Revenue Growth
--38.95%
Other R&D Services Revenue
-23.50M
Other R&D Services Revenue Growth
-135.00%
Collaborative Agreement Revenue
465.80M332.60M
Collaborative Agreement Revenue Growth
40.05%-5.67%
Eplontersen Joint Development Revenue
42.10M79.40M
Eplontersen Joint Development Revenue Growth
-46.98%-37.18%
Total R&D Revenue
507.90M412.00M
Total R&D Revenue Growth
23.28%-13.99%
Revenue (Other)
-672.29M-432.16M
Revenue (Total)
943.71M705.14M
Revenue (Total) Growth
33.83%-10.47%
Updated Feb 25, 2026. Data Source: Fiscal.ai.